Reviewing Madrigal Pharmaceuticals Inc. (MDGL)’s and Liquidia Technologies Inc. (NASDAQ:LQDA)’s results

This is a contrast between Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Liquidia Technologies Inc. (NASDAQ:LQDA) based on their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Madrigal Pharmaceuticals Inc. 98 0.00 6.23M -2.73 0.00
Liquidia Technologies Inc. 4 0.00 7.41M -2.51 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Madrigal Pharmaceuticals Inc. and Liquidia Technologies Inc.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals Inc. 6,331,944.30% -8.7% -8.5%
Liquidia Technologies Inc. 178,052,238.27% -222.5% -78.3%

Liquidity

Madrigal Pharmaceuticals Inc.’s Current Ratio is 45.8 while its Quick Ratio is 45.8. On the competitive side is, Liquidia Technologies Inc. which has a 5.6 Current Ratio and a 5.6 Quick Ratio. Madrigal Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Liquidia Technologies Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Madrigal Pharmaceuticals Inc. and Liquidia Technologies Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Madrigal Pharmaceuticals Inc. 0 0 1 3.00
Liquidia Technologies Inc. 0 0 0 0.00

Madrigal Pharmaceuticals Inc.’s upside potential is 26.45% at a $147 average price target.

Institutional & Insider Ownership

Institutional investors held 98.9% of Madrigal Pharmaceuticals Inc. shares and 61.4% of Liquidia Technologies Inc. shares. 11.33% are Madrigal Pharmaceuticals Inc.’s share held by insiders. On the other hand, insiders held about 1.1% of Liquidia Technologies Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Madrigal Pharmaceuticals Inc. -2.48% -18.06% -15.35% -22.83% -66.44% -22.56%
Liquidia Technologies Inc. -1.88% -8.17% -24.48% -47.03% -33.55% -66.25%

For the past year Madrigal Pharmaceuticals Inc. has stronger performance than Liquidia Technologies Inc.

Summary

Madrigal Pharmaceuticals Inc. beats Liquidia Technologies Inc. on 6 of the 10 factors.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß (THR-ß) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.